MedTrace Logo

Shrinking the Anterior Border of CTV2 for Nasopharyngeal Carcinoma to Reduce the Radiation of Nasal Cavity

NCT07072000 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 550

Last updated 2025-07-18

No results posted yet for this study

Summary

This is a an open-label, non-inferiority, multicenter, randomized phase III trial aimed to explore the efficacy and safety of shrinking the anterior border of CTV2 in nasopharyngeal carcinoma patients without tumor invasion into the posterior nasal aperture.

Conditions

  • Nasopharyngeal Cancinoma (NPC)

Interventions

RADIATION

standard CTV delineation

The anterior border of CTV2 is delineated at the posterior 1/3 of the nasal cavity.

RADIATION

reduced CTV delineation

The anterior border of CTV2 is defined as 5 mm anterior to the posterior nasal cavity anteriorly from the choanae.

Sponsors & Collaborators

  • First People's Hospital of Foshan

    collaborator OTHER

  • Affiliated Hospital of Guangdong Medical University

    collaborator OTHER

  • The Wuzhou Red Cross Hospital

    collaborator UNKNOWN

  • The Fourth Affiliated Hospital of Guangxi Medical University

    collaborator UNKNOWN

  • Zhongshan City People 's Hospital

    collaborator UNKNOWN

  • Hai-Qiang Mai,MD,PhD

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-01
Primary Completion
2030-07-31
Completion
2032-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07072000 on ClinicalTrials.gov